HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Antibiotic-associated diarrhea — Clinical Guidelines

Overview

Antibiotic-associated diarrhea (AAD) is a common adverse effect of antibiotic use, characterized by diarrhea occurring during or shortly after antibiotic treatment, often due to disruption of the gut microbiota. 2 3

Diagnosis

Clinical Presentation: Diarrhea onset during or shortly after antibiotic therapy.

Epidemiological Context: History of recent antibiotic use, particularly broad-spectrum antibiotics.

Laboratory Tests: Not routinely required but may include stool cultures to rule out Clostridioides difficile infection.

Specific Antibiotic Risk: Higher risk with lincomycins, third-generation cephalosporins, and first/second-generation cephalosporins (ROR values indicate significant association). 2

Management

First-Line Treatment: Discontinue the offending antibiotic if possible.

Adjunctive Therapies:

- Probiotics: Use of antibiotics containing protected lactobacilli can reduce incidence (e.g., ampicillin + cloxacillin with lactobacilli). 3 - Specific Antibiotics: No specific antibiotic treatment recommended universally; focus on supportive care and addressing underlying causes like C. difficile if suspected.

Special Populations

Elderly: Higher susceptibility to AAD; careful monitoring and consideration of probiotic prophylaxis may be beneficial. 3

No Specific Data: Limited evidence directly addressing pediatrics or pregnancy in the provided abstracts.

Key Recommendations

Monitor Patients on Broad-Spectrum Antibiotics for signs of AAD, particularly those receiving lincomycins, third-generation cephalosporins, and first/second-generation cephalosporins. (Evidence: Moderate 2)

Consider Probiotic Prophylaxis in high-risk patients, such as those receiving antibiotics known to significantly increase AAD risk, to potentially reduce incidence. (Evidence: Moderate 3)

Evaluate for Clostridioides difficile in patients with severe or persistent diarrhea post-antibiotic use, especially if symptoms suggest pseudomembranous colitis. (Evidence: Expert opinion)

References

1 Coste A, Wong AYS, Haguinet F, Bate A, Douglas IJ. Performance of the Self-Controlled Case Series for Drug Safety Signal Detection: A Multi-Database Study. Pharmacoepidemiology and drug safety 2026. link 2 Huang H, Li L, Wu M, Liu Z, Zhao Y, Peng J et al.. Antibiotics and antibiotic-associated diarrhea: a real-world disproportionality study of the FDA adverse event reporting system from 2004 to 2022. BMC pharmacology & toxicology 2023. link 3 Ahuja MC, Khamar B. Antibiotic associated diarrhoea: a controlled study comparing plain antibiotic with those containing protected lactobacilli. Journal of the Indian Medical Association 2002. link

Antibiotic-associated diarrhea